Immune checkpoint inhibitors (ICI) targeting programmed death (PD)-1 and programmed death ligand (PD-L1) have become a component of standard front-line therapy for metastatic1,2, locally advanced3,4, and resectable5,6 non-small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.